Recombinant COVID-19 Protein Vaccine (Sf9 Cell) (Chengdu WestVac)

新冠病毒重组蛋白疫苗(Sf9细胞)(成都威斯克)

Report date: 2025/07/08 13:31:53

Base Information

Drug NameRecombinant COVID-19 Protein Vaccine (Sf9 Cell) (Chengdu WestVac)
Drug Alias NameRecombinant COVID-19 vaccine (Sf9 cells) (Chengdu WestVac)重组新型冠状病毒疫苗（Sf9细胞）(成都威斯克)威克欣WSK-V101
ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionCoronavirus spike glycoprotein inhibitorsImmunostimulants
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2022/12/05
Country/TerritoryPhilippinesNepalMexico +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChengdu WestVac Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu WestVac Biopharma Co LtdWest China Hospital Of Sichuan University
Inactive CompaniesJiangsu Provincial Center For Disease Control And Prevention
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A